MapLight Therapeutics (MPLT) General Counsel reports 26,007-share tax withholding

Rhea-AI Filing Summary

MapLight Therapeutics General Counsel Kristopher Hanson reported a tax-related share withholding tied to restricted stock units. On January 27, 2026, the issuer withheld 26,007 shares of Voting Common Stock at $17.98 per share to cover tax obligations from RSU settlement.

After this transaction, Hanson beneficially owned 183,852 shares directly. The remaining securities he holds are still subject to a 180-day IPO lock-up following the final prospectus dated October 26, 2025, limiting his ability to sell or transfer those shares during that period.

Insider Trade Summary

Net Seller: 26,007 shares

Net Sell 1 txn

Insider Hanson Kristopher

Role General Counsel

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Voting Common Stock	26,007	$17.98	$468K

Holdings After Transaction: Voting Common Stock — 183,852 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock unit awards. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

FAQ

What insider transaction did MapLight Therapeutics (MPLT) report for Kristopher Hanson?

MapLight Therapeutics reported that General Counsel Kristopher Hanson had 26,007 shares of Voting Common Stock withheld by the company to cover tax obligations from restricted stock unit settlement. This is a tax withholding event, not an open-market sale or discretionary stock disposal.

How many MapLight Therapeutics (MPLT) shares does Kristopher Hanson own after this Form 4?

After the transaction, General Counsel Kristopher Hanson beneficially owned 183,852 shares of MapLight Therapeutics Voting Common Stock directly. This figure reflects his holdings following the 26,007-share withholding for taxes connected to restricted stock unit settlement on January 27, 2026.

Was the MapLight Therapeutics (MPLT) Form 4 transaction an open-market sale?

The Form 4 transaction was not an open-market sale. The 26,007 MPLT shares were withheld by the issuer to satisfy tax withholding obligations from restricted stock unit settlement, meaning the shares were retained by the company rather than sold on the open market.

At what price were Kristopher Hanson’s withheld MPLT shares valued on the Form 4?

The 26,007 withheld shares of MapLight Therapeutics Voting Common Stock were valued at $17.98 per share. This price is used on the Form 4 to calculate the value of shares retained by the issuer for tax withholding related to restricted stock unit settlement.

Is Kristopher Hanson subject to a lock-up on his MapLight Therapeutics (MPLT) shares?

Yes. The securities of MapLight Therapeutics retained by Kristopher Hanson remain subject to a 180-day lock-up agreement following the company’s IPO final prospectus dated October 26, 2025, restricting most direct or indirect sales or transfers during that period.

What role does Kristopher Hanson hold at MapLight Therapeutics (MPLT)?

Kristopher Hanson serves as an officer of MapLight Therapeutics, holding the position of General Counsel. His Form 4 filing reflects a tax-related share withholding transaction connected to his equity compensation in the form of restricted stock unit awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/29/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hanson Kristopher

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	01/27/2026		F		26,007(1)	D	$17.98	183,852	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock unit awards. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

	/s/ Kristopher L. Hanson	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.